Other substances

Dutasteride

A selective steroid 5alpha-reductase inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
5
 AI-suggested references
1
 Clinical trials

General information

Dutasteride is a synthetic compound used for treatment of symptomatic benign prostatic hyperplasia. It blocks conversion of testosterone to 5alpha-dihydrotestosterone (ChEBI).

Dutasteride on DrugBank
Dutasteride on PubChem
Dutasteride on Wikipedia

Marketed as

AVODART; DUTASTERIDE

 

Structure image - Dutasteride

C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C

Supporting references

Link Tested on Impact factor Notes Publication date
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
in silico 3.31 Aug/05/2020
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Small molecule Randomized controlled double-blind trial Moderate severity Mild severity 		Male outpatients

Outpatients in the treatment group had statistically significantly shortened COVID-19 duration, reduced viral shedding, improved oxygen saturation, and decreased inflammatory marker levels. Sample size: 43 + 44 placebo (both groups undergoing early nitazoxanide and azithromycin therapy). Dosage: 0.5 mg daily or until full COVID-19 remission.


 Feb/01/2021

AI-suggested references

Link Publication date
Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
Jan/25/2021
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Oct/21/2020
Repurposing existing drugs for COVID-19: an endocrinology perspective.
Sep/29/2020
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical)
Jan/27/2021
In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry
Dec/02/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04729491 EAT-DUTA AndroCoV Trial Completed Phase 2|Phase 3 Jun/30/2020 Oct/07/2020
  • Alternative id - CORPO-AB-DRUG-SARS-004B
  • Interventions - Drug: Dutasteride 0.5 mg|Drug: Azithromycin|Drug: Nitazoxanide|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Corpometria Institute, Brasília, DF, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 138
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death]|Time-to-recovery|SARS-CoV-2 viral load|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of vasopressors use|Proportion of deaths|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to baseline (Day 0))|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to baseline (Day 0))|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Variation in oxygen saturation compared to baseline (Day 0)|Disease duration|Change in viral load from baseline to Day 5|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms
Export (.csv)